To access the anti-tumor efficacy, safety and tolerability of Sunvozertinib combined with chemotherapy in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) sensitizing mutations who have progressed following standard TKI therapy.
To provide a signed and dated, written informed consent.
80≥Age ≥ 18 years old
Histologically or cytologically confirmed non-squamous NSCLC with documented EGFR mutations from a local laboratory
EGFR-sensitive mutations including exon 19 deletion and exon 21 L858R mutated, and exon 20 T790M mutated.
Spinal cord compression or meningeal metastasis
A history of malignant tumors within 2 years.
With known resistant mutations that have approved target therapy
Recover from AEs caused by previous treatment